Lamivudine treatment for acute hepatitis B virus infection during allogeneic peripheral blood stem cell transplantation

Efremov, Dimitar G.; Georgievski, Borce; Čevreska, Lidija; Pivkova, Aleksandra; Panovska, I

doi:10.1038/sj.bmt.1703909

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, five trials [20][21][22][23][24] met the inclusion criteria for the meta-analysis (Figure 1). We excluded seven trials from the review because the population did not meet eligibility criteria and were not clinical trials [25][26][27][28][29][30][31].…”

Section: Resultsmentioning

confidence: 99%

Lamivudine and Entecavir for Acute Hepatitis B: A Systematic Review and Meta-Analysis

Henriquez-Camacho,

Hijas-Gomez,

Risco Risco

et al. 2023

Viruses

View full text Add to dashboard Cite

Background. Acute hepatitis B infection is associated with severe liver disease and chronic sequelae in some cases. The purpose of this review was to determine the efficacy of nucleoside analogues (NA) (lamivudine versus entecavir) compared to placebo or no intervention for treating acute primary HBV infection. Methods. A meta-analysis for drug intervention was performed, following a fixed-effect model. Randomized controlled trials (RCTs) and quasi-randomized studies that evaluated the outcomes of NA in acute hepatitis B infection were included. The following outcomes were considered: virological cure (PCR negative), elimination of acute infection (seroconversion of HBsAg), mortality, and serious adverse events. Results. Five trials with 627 adult participants with severe acute hepatitis B defined by biochemical and serologic parameters were included. Virological cure did not favor any intervention: OR 0.96, 95% CI 0.54 to 1.7 (p = 0.90), I2 = 58%. Seroconversion of HBsAg to negative favored placebo/standard-of-care compared to lamivudine: OR 0.54, 95% CI 0.33 to 0.9 (p = 0.02), I2 = 31%. The only trial that compared entecavir and lamivudine favored entecavir over lamivudine (OR: 3.64, 95% CI 1.31–10.13; 90 participants). Adverse events were mild. Conclusion. There is insufficient evidence that NA obtain superior efficacy compared with placebo/standard-of-care in patients with acute viral hepatitis, based on low quality evidence.

show abstract

Section: Resultsmentioning

confidence: 99%

Lamivudine and Entecavir for Acute Hepatitis B: A Systematic Review and Meta-Analysis

Henriquez-Camacho,

Hijas-Gomez,

Risco Risco

et al. 2023

Viruses

View full text Add to dashboard Cite

show abstract

“…Nevertheless, lamivudine has the most available data evaluating its use in acute hepatitis B among the oral antiviral agents. Although much of the data are limited to case reports [12,13] and case series [14,15], mostly involving immunocompromised patients with hematologic malignancies [16], transplant recipients [17][18][19][20][21][22], or patients with extrahepatic manifestations of the disease [23,24], a few small studies have been published with reports of good outcomes in immunocompetent individuals.…”

Section: Lamivudinementioning

confidence: 97%

Treatment of Acute Hepatitis B with Nucleoside and/or Nucleotide Analogues

2010

Curr Hepatitis Rep

View full text Add to dashboard Cite

Acute infection with the hepatitis B virus resolves in 95% of adults with no need for specific medical therapy. However, a few cases present as severe hepatitis or acute liver failure, which may require orthotopic liver transplantation or cause death. Under these circumstances, medical therapy that can improve the clinical outcome and improve spontaneous survival would be highly useful; yet, published data regarding the utility of antiviral therapy in acute hepatitis B is quite limited. In this paper, the efficacy and safety of oral nucleoside and nucleotide analogues in the treatment of acute hepatitis B are reviewed, and guidelines for treatment of these acute cases are revisited.

show abstract

Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO)

Sandherr¹,

et al. 2006

View full text Add to dashboard Cite

Morbidity and mortality in patients with malignancies are increased by viral infections. These mostly are reactivations of asymptomatic latent infections. They primarily concern clinical entities associated with the reactivation of herpes viruses, such as varicella zoster virus (VZV) and cytomegalovirus (CMV). Respiratory tract infections caused by influenza, parainfluenza or respiratory syncytial virus (RSV) are less common. Since reactivation of latent infections has major clinical impact, antiviral prophylaxis is an attractive approach for patients expecting immunosuppression. The main risk factor for clinically relevant reactivation is profound disruption of cellular immune response. Duration and severity of chemotherapy induced neutropenia are of lesser importance. The risk of viral complications rises significantly in the presence of sustained suppression of T-cell function, e.g. in recipients of allogeneic stem cell transplants or of alemtuzumab (Campath-1H) antibody therapy. The objective of this guideline is to review the basis of prophylactic strategies and to provide recommendations for clinicians treating patients with haematological malignancies and solid tumors.

show abstract

Lamivudine treatment for acute hepatitis B virus infection during allogeneic peripheral blood stem cell transplantation

Cited by 4 publications

References 9 publications

Lamivudine and Entecavir for Acute Hepatitis B: A Systematic Review and Meta-Analysis

Lamivudine and Entecavir for Acute Hepatitis B: A Systematic Review and Meta-Analysis

Treatment of Acute Hepatitis B with Nucleoside and/or Nucleotide Analogues

Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO)

Contact Info

Product

Resources

About